




Attorney's Docket No. **D0590/7003**
(formerly B0192/7010)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Plaetinck et al.
Serial No : 09/347,311
Filed : July 2, 1999
For : CHARACTERISATION OF GENE FUNCTION USING DOUBLE
STRANDED RNA INHIBITION
Examiner : R. Shukla
Art Unit : 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 4th day of January, 2001.



Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

STATEMENT PURSUANT TO 37 CFR 1.821(f) AND 37 CFR 1.825 (a) and (b)

This statement is made pursuant to 37 CFR 1.821 (f), and 37 CFR 1.825 (a) and (b). Applicants submit herewith a substitute copy of the written sequence listing and a computer readable diskette to comply with the sequence requirements. The amendments to the sequence listing relate only to listing oligonucleotide sequences which were disclosed in the specification but not previously listed on the Sequence Listing. No new matter has been added.

Applicants' attorney states that the information recorded in computer readable form is identical to the written sequence listing and that neither the computer readable form nor the written sequence listing contain new matter.

Respectfully submitted,



John R. Van Amsterdam, Reg. No. 40,212
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: (617) 720-3500

Attorney Docket No.: D0590/7003
Dated: January 4, 2001
x01/04/01